Introduction: Breast cancer is leading cancer in women, and the incidence of breast cancer in India is on the rise. The most common histologic type of breast cancer is infiltrating ductal carcinoma. Prognostic and predictive factors are used in the management of breast cancer. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/neu) are immunohistochemical markers of prognosis as well as predictors of response to therapy. Aims and Objectives: The study was conducted to evaluate ER, PR, and HER2/neu expressions in invasive ductal carcinomas of the breast by immunohistochemistry, to explore the correlation of these markers to each other and to various clinicopathological parameters: age of the patient, histological grade, tumor size, and lymph node metastasis. Materials and Methods: This prospective study was conducted on 100 cases of infiltrating ductal carcinoma. Slides were prepared from blocks containing cancer tissue, and immunohistochemical staining was done for ER, PR, and HER2/neu expressions. Interpretation of expressions was done using Allred scoring system for ER/PR and the American Society of Clinical Oncology/College of American Pathologists guidelines for HER2/neu. Statistical analysis was performed to determine the statistical significance by applying Chi-square test. Results: Majority of tumors were ER and PR positive and HER2/neu negative. ER and PR correlated significantly with age, tumor size, and tumor grade; whereas, HER2/neu correlated significantly with tumor size only. No association was seen with axillary lymph node metastasis. ER and PR expression correlated with each other, but none correlated with HER2/neu. Conclusions: As the majority of the tumors are ER, PR positive and since ER and PR correlate with each other as well as with age, tumor size, and grade. Therefore, routine assessment of hormone receptors is recommended for prognostic and therapeutic information in breast cancer cases.

Keywords: Allred scoring system, human epidermal growth factor, immunohistochemical markers, estrogen receptors, progesterone receptors

Address for correspondence: Dr. Prem Chand, Departments of General Surgery and Pathology, Government Medical College, Patiala, Punjab, India.
E-mail: premchandsingl@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Chand P, Garg A, Singla V, Rani N. Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. Niger J Surg 2018;24:100-6.
metastasis. Nowadays, more importance is given to biological molecular prognostic factors because a significant number of patients with early-stage breast cancer harbor microscopic metastasis at the time of diagnosis.\(^4\) Hormone receptors (ER and PR) and human epidermal growth factor receptor-2 (HER-2) are the most relevant clinical biomarkers that are widely used in stratifying breast cancer cases management.\(^5\) Knowledge of hormone receptors and HER-2 expressions are vital for breast cancer management plans and decision-making.\(^5\) Prognostic and predictive factors are used in the management of breast cancer. Prognostic factors are those which influence patient’s overall outcome such as chances of recurrence after treatment. These factors help in the selection of patients for a specific treatment.\(^6\) Predictive factors evaluate the likelihood of benefit from a specific treatment. ER, PR, and HER2/neu are prognostic as well as predictive factors.\(^6\)

**Oestrogen receptor**

Breasts undergo important physiological changes during a woman’s lifespan, and these changes are actively mediated by estrogen. ER is of two types – ER\(\alpha\) and ER\(\beta\).\(^7\) Receptor ER\(\alpha\) is a well-established prognostic and predictive factor in breast cancer. The prognostic significance of ER\(\beta\) is not well defined.\(^7,8\) The majority of ER-positive breast cancers contain both ER\(\alpha\) and ER\(\beta\) subtypes; although, some cancers have only ER\(\beta\) expression. This may lead to distinct clinical behaviors and responses. It is observed that in contrast to ER\(\alpha\), ER\(\beta\) expression declines during breast carcinogenesis.\(^9\)

**Progesterone receptor**

PR is of two types as follows: PR-A and PR-B. Progesterone acts as a modulator of estrogen function.\(^10\) It is observed that ER-positive breast cancers which lack PR expression, are less responsive to hormonal treatment than those that are PR positive. It is also seen that ER and PR are not stable phenotypes. These can change over the natural history of the disease or as consequence of treatment.\(^11\)

**Human epidermal growth factor receptor-2/neu (c-erbB-2)**

It is a member of the four-member family of closely related growth factor receptors, including epidermal growth factor receptor or HER1, HER2, HER3, and HER4. HER2/neu amplification or overexpression is involved in oncogenic transformation and tumorigenesis in breast cancer. Inappropriately increased signaling occurs as a result of receptor overexpression. It may lead to increased and uncontrolled cell proliferation, decreased apoptosis, increased cancer cell motility, and angiogenesis and hence worse prognosis.\(^12\)

At present, determining ER, PR, and HER2/neu receptor status in breast cancer have become a common practice, as there is a survival advantage for patients with hormones receptor positive status by treatment with adjuvant hormonal or chemotherapeutic regimens. It is well known that strong ER-positive cases benefit from endocrine therapy alone, in contrast to those with low to moderate ER positivity. PR status is independently associated with disease-free and overall survival. Patients with ER, PR-positive tumors have a better prognosis than patients with ER, PR-negative tumors.\(^13\)

The present study was conducted to correlate the expression of ER, PR, and HER2/neu with each other and to various clinicopathological parameters as follows: age of the patient, histological grade, tumor size, and lymph node metastasis.

**Materials and Methods**

Hundred patients with a diagnosis of infiltrating ductal carcinoma breast were enrolled for the study. Written
informed consent was obtained from all patients. We analyzed the expression of ER, PR, and HER2/neu by immunohistochemistry (IHC), with each other and to various clinicopathological parameters.

**Inclusion criteria**
All patients with infiltrating ductal carcinoma of the breast confirmed histopathologically were included in the study.

**Exclusion criteria**
Patients with inflammatory breast lesions, posttraumatic breast lesions, benign breast diseases and patients with breast cancer who received neoadjuvant chemotherapy were excluded from the study.

**Procedure**
Paraffin blocks containing cancer tissue were selected from histopathologically confirmed cases of infiltrating ductal carcinoma. After preparing slides from blocks, immunohistochemical staining was done for ER, PR, and HER2/neu by standard procedure.[14]

**Preparation of slides**
Paraffin sections were cut and mounted on silanized slides. Slides were melted at 65°C and then dipped into xylene to remove the paraffin. After rehydrating tissues, slides were washed with distilled water. Then, slides were dipped into a fresh aqueous solution of 3% peroxide for 3 min and rinsed with Tris buffer.

**Antigen retrieval and detection of antigens**
Heat retrieval was done with citrate buffer in the Decloaking chamber for 40 min at 95°C and then brought to room temperature after removing from the Decloaking chamber and by placing the slides in Tris-Saline buffer. 1% mouse serum was added to the tissue section to block nonspecific immunostaining. The sections were exposed to the primary antibody for about 1 h, and then primary antibody was washed with Tris buffer.

**Secondary detection of the primary antibody**
Sections were incubated with biotinylated mouse anti-species antibody for 10 min, and then rinsed in Tris buffer. A solution of chromogen, 3, 3'-diaminobenzidine (DAB) at 1 mg/ml in Tris buffer with 0.016% fresh H₂O₂ was prepared and added to the slides. DAB from the slides was washed with tap water.

**Counterstaining**
A solution of hematoxylin diluted 1:1 with distilled water was made slides were dipped into hematoxylin solution for staining. Then, slides were washed in distilled water and dehydrated by dipping in ethanol. Washed in xylene and coverslip was applied for viewing and reporting [Figure 1].

**Reporting**
Reporting done as per ER/PR scoring system and criteria as per Allred scoring system[15]

**Proportion score**
0 – No cells are ER +ve.
1 – ≤1% of cells are ER +ve.
2 – 1%–10% of cells are ER +ve.
3 – 11%–33% of cells are ER +ve.
4 – 34%–66% of cells are ER +ve.
5 – 67%–100% of cells are ER +ve.

**Intensity score**
0 – Negative.
1 – Weak.
2 – Intermediate.
3 – Strong.

**Interpretation**
Total (proportion score + intensity score).
0–2 = Negative; 3–8 = Positive

**Human epidermal growth factor receptor-2/neu scoring system and criteria according to the American Society of Clinical Oncology College of American Pathologists guidelines[16]**
0 = no staining or incomplete faint and barely perceptible in < 10% of tumor cells.
1+ = incomplete membrane staining which is faint and barely perceptible and within >10% of tumor cells.
2+ = circumferential membrane staining that is incomplete and/or weak/moderate and within >10% of the invasive tumor cells; or complete and circumferential membrane staining that is intense and within ≤10% of the invasive tumor cells.
3+ = circumferential, complete, and intense staining and within >10% of tumor cells.

FISH is required for equivocal HER2/neu positivity. Hence, HER2/neu 2+ was taken as negative along with her2/neu 0 and 1+. Only 3+ on IHC was taken as positive.

**Statistical analysis**
Chi-square test was used to determine the statistical significance between ER/PR status and HER2/neu status along with their correlation with various clinicopathological parameters such as patient’s age, axillary lymph node status, tumor size, and tumor grade with respect to infiltrating ductal carcinoma.
breast. A value of \( P < 0.05 \) was considered as statistically significant.

**Results**

**Age**

Patients were in the age group between 24 and 80 years, with mean age 55.28 years. The majority (66%) were in the older age group >50 years. About 96%, ER, and PR positive cases were of age >40 years. Majority HER2/neu positive were of age <40 years [Table 1]. It was statistically concluded that ER, PR, and HER2/neu expression was significantly correlated with age [Table 1].

**Tumour size**

The average tumor size was 4.3 cm. Majority of ER/PR positive (46%–47%) tumors were of size between 2 and 5 cm, and majority of HER2/neu positive (71.43%) tumors were of size <2 cm. Correlation of expression of ER, PR, and HER2/neu compared to tumor size [Table 2], was statistically significant.

**Tumour grade**

In our study, according to Nottingham Modified Bloom–Richardson System score, majority tumors were in Grade II (43%) followed by Grade III (31%) and then Grade I (26%). Majority of ER/PR positive (48%–49%) tumors were of Grade II, and the majority of HER2/neu positive (57.14%) tumors were of Grade III. Correlation of expression of ER, PR, and HER2/neu compared to tumor grade is shown in Table 3. It was concluded that ER/PR expression compared to tumor grade was statistically significant and HER/neu was not significant.

**Axillary lymphnode status**

All cases were evaluated for axillary lymph nodes metastasis and found that 38 patients had lymph nodes metastasis. Out of 63 ER-positive cases,

| Age (years) | ER | PR | HER2/neu |
|-------------|----|----|----------|
| <40         | 2  | 2  | 5        |
| 41-50       | 9  | 9  | 1        |
| 51-60       | 24 | 22 | 1        |
| >60         | 28 | 25 | 0        |
| Total       | 63 | 58 | 7        |

| Tumour size (cm) | ER | PR | HER2/neu |
|------------------|----|----|----------|
| <2               | 23 | 21 | 5        |
| 2-5              | 30 | 27 | 2        |
| >5               | 10 | 10 | 0        |
| Total            | 63 | 58 | 7        |

| Grade | ER | PR | HER2/neu |
|-------|----|----|----------|
| I     | 20 | 18 | 1        |
| II    | 31 | 28 | 2        |
| III   | 12 | 12 | 4        |
| Total | 63 | 58 | 7        |

ER: Estrogen receptors, PR: Progesterone receptor, HER2/neu: Human epidermal growth factor receptor

**Table 1: Estrogen receptors, progesterone receptor and human epidermal growth factor receptor expression compared to age**

**Table 2: Estrogen receptors, progesterone receptor and human epidermal growth factor receptor expression compared to tumour size**

**Table 3: Estrogen receptors, progesterone receptor and human epidermal growth factor receptor expression compared to tumour grade**
25 had positive axillary lymph nodes, whereas out of 58 PR positive cases 23 had positive axillary lymph nodes. Out of 7 HER2/neu positive cases, 2 had positive axillary lymph nodes. It was concluded that correlation of expression of ER, PR, and HER2/neu compared to axillary lymph node status [Table 4], was not significant.

**Oestrogen receptor status**

Sixty-three tumors were ER-positive and 37 were ER negative. ER-positive tumors showed weak, moderate to strong nuclear positivity in >1% of tumor cells.

**Progesterone receptor status**

Fifty-eight tumors were PR positive and 42 were PR negative. PR positive cases showed weak, moderate to strong nuclear positivity in >1% of tumor cells.

Out of 100 cases, 58 cases were ER and PR positive, 37 cases negative and 5 cases showed different expressions of ER and PR. On statistical analysis, it was observed that $\kappa = 0.854$; asymptotic standard error = 0.053; $P = 0.000$ and using kappa as a measure of agreement, it was concluded that expressions of ER/PR and HER2/neu do not agree with each other.

**HER2/neu expression**

Seven patients were HER2/neu positive, and 93 were HER2/neu negative. Only 2 cases were ER, PR, and HER2/neu positive. A total of 32 cases were both ER and HER2/neu negative. Sixty-Six cases showed different expressions of ER and HER2/neu [Table 5]. Out of 100 cases, only 2 cases were both PR as well as HER2/neu positive, 38 cases were both PR and HER2/neu negative, and 60 cases showed different expressions of PR and HER2/neu. On statistical analysis using kappa as measure of agreement, it is concluded that expressions of ER/PR and HER2/neu do not agree with each other.

**DISCUSSION**

Breast cancer is leading cancer in women accounting for 25% of all cases worldwide and leading cause of death due to carcinoma in women. It is more common in developed countries.[1,2,5,17] Outcomes for breast cancer vary greatly depending on the cancer type, extent of disease and person’s age. Five years survival rates in the developed world are high, 80% and 90%, in England and the United States, respectively.[18] In developing countries, survival rates are poor. This can be attributed to the lack of effective screening programmes and lack of awareness regarding signs and symptoms of breast lump, which leads to advanced disease with larger tumor size and nodal involvement at presentation.[19]

Data from India indicate that among females, the most common site of cancer is the cervix, with the second most common site being the breast. The mainstay of breast cancer treatment is surgery when a tumor is localized, followed by chemotherapy (when indicated), radiotherapy and for ER and PR positive tumors, adjuvant hormonal therapy.[14] ER, PR, and HER2/neu are immunohistochemical markers of prognosis as well as predictors of response to therapy. At present also, determining ER, PR, and Her2/neu receptor status in breast cancer have become common practice as there is a survival advantage for patients with hormones receptor positive status by treatment with adjuvant hormonal or

---

**Table 4: Expression of estrogen receptors, progesterone receptor and human epidermal growth factor receptor compared to axillary lymph node status**

| Lymph node status | ER Positive | ER Negative | Total | PR Positive | PR Negative | Total | HER2/neu Positive | HER2/neu Negative | Total |
|-------------------|-------------|-------------|-------|-------------|-------------|-------|-------------------|-------------------|-------|
| Positive          | 25          | 13          | 38    | 23          | 15          | 38    | 2                 | 36                | 38    |
| Negative          | 38          | 24          | 62    | 35          | 27          | 62    | 5                 | 57                | 62    |
| Total             | 63          | 37          | 100   | 58          | 42          | 100   | 7                 | 93                | 100   |

$\chi^2$, df, $P$ = 0.205, 1, 0.651; 0.161, 1, 0.689; 0.284, 1, 0.594

**Table 5: Estrogen receptors and progesterone receptor expression compared to human epidermal growth factor receptor expression**

| ER/HER2/neu | HER2/neu positive | HER2/neu negative | Total | PR/HER2/neu | HER2/neu positive | HER2/neu negative | Total |
|-------------|-------------------|-------------------|-------|-------------|-------------------|-------------------|-------|
| ER positive | 2                 | 61                | 63    | PR positive | 2                 | 56                | 58    |
| ER negative | 5                 | 32                | 37    | PR negative | 5                 | 37                | 42    |
| Total       | 7                 | 93                | 100   | Total       | 7                 | 93                | 100   |

$\kappa$, ASE, $P$ = 0.079, 0.048, 0.058; 0.072, 0.048, 0.102

ER: Estrogen receptors, PR: Progesterone receptor, HER2/neu: Human epidermal growth factor receptor, ASE: Asymptotic standard error
chemotherapeutic regimens. Patients with ER PR positive tumors have a better prognosis than patients with ER PR negative tumors.[13]

The present study was conducted to observe the correlation of expression of ER, PR, and HER2/neu with each other and to various clinicopathological parameters: age of the patient, histological grade, tumor size, and lymph node metastasis.

**Age**

More than two-thirds of breast cancer cases are diagnosed in women aged 50 years and older; the majority of these cases are in developed countries. For women aged 15–49 years, twice as many breast cancer cases are diagnosed in developing countries than in developed countries.[20] In countries where mammography is available and affordable, adherence to recommendations for routine screening is associated with reduced mortality from breast cancer.[20]

In the present study, infiltrating ductal carcinoma seen in the age group between 24 and 80 years, with mean age 55.28 years is similar to study conducted by Sengal et al.[5] and Kaul et al.[21] Majority of ER and PR positive cases were of age >60 years, as seen in a study conducted by Alzaman et al.[22] about 71% HER2/neu positive were of age <40 years, similar to Alzaman et al.[22] observations. A significant correlation was observed between the age of the patient and ER (P = 0.000) and PR (P = 0.000) expression as shown in studies by Dodiya et al.[23] and Ghosh et al.[24] Significant correlation was also observed between the age of the patient and HER2/neu expression (P = 0.000), similar to study conducted by Ramić et al.[25]

**Tumor size**

Tumor size was 0.1–12 cm, with average size 4.3 cm. Forty-three had sizes ranging from 2 to 5 cm. 47.61% of ER-positive and 46.55% of PR positive tumors were of size 2–5 cm. 71.43% of HER2/neu tumors were of size <2 cm. There was seen significant correlation between tumor size and ER (P = 0.001), PR (P = 0.014) expression in the present study. Similar to Almasri and Hamad et al.[26] study, a significant correlation was seen between tumor size and HER2/neu expression (P = 0.028) in the present study.

**Tumour grade**

Forty-three tumors were Grade II, 31 Grade III and 26 Grade I. Majority of ER-positive (49.21%) and the majority of PR positive (31.03%) tumors were of Grade II, but the majority of HER2/neu positive (57.14%) tumors were of Grade III. A study conducted by Siadati et al.[27] showed similar results. There was seen significant correlation between tumor grade with ER (P = 0.003) and PR (P = 0.031). The study done by Dodiya et al.[23] showed similar results. No association was seen between tumor grade and HER2/neu expression (P = 0.298) similar to study done by Dodiya et al.[23]

**Axillary lymph node status**

Metastasis in axillary lymph nodes was seen in 38% of patients. Out of ER and PR positive cases about 39% had positive axillary lymph nodes positive for metastasis. About 28.57% of HER2/neu positive cases had positive axillary lymph nodes for metastasis. Study conducted by Ali et al.[28] showed similar results. As shown in Table 4, no significant correlation was observed between axillary lymph node status with ER (P = 0.651), PR (P = 0.689), and HER2/neu (P = 0.594) expression, similar to studies conducted by Azizun-Nisa et al.[29]

**Receptor positivity**

In the present study, ER positivity was 63%, closely matched the results of the study conducted by Idrisinghe et al.[30] and PR positivity was 58%, closely matched the results of the study conducted by Engstrom et al.[31] HER2/neu positivity was only 7% was much lower as compared to other studies. The possible explanation for this is due to variations in different populations. In addition, HER2/neu assay results are influenced by multiple biologic, technical and performance factors. Since many aspects of HER2/neu assays have not been standardized, the effects of these disparate influences could not be isolated. ER and PR correlated with each other (P = 0.000), whereas expression of HER2/neu was inversely related to ER (P = 0.058) and PR expression (P = 0.102). Similar results were found in studies conducted by Siadati et al.[27] Maha[32] etc.

**Conclusions**

Invasive ductal carcinomas of the breast was seen in the age of 24–80 years, with a mean age was 55.28 years. The maximum number of cases were seen in the age above >50 years (66%). Majority of tumors were ER and PR positive and HER2/neu negative. Majority of ER and PR positive tumors were of Grade II; whereas, the majority of HER2/neu positive tumors were of Grade III. The present study confirmed that ER and PR are correlated with age, tumor size, and tumor grade but not with lymph node status. HER2/neu expression correlated with age and tumor size but not with tumor grade and lymph node status. ER and PR expression correlated with each other, but none were correlated with HER2/neu. ER and PR positive cases may have a favorable outcome with adjuvant hormonal therapy.
Assessment of hormone receptors for clinical management of breast cancer patient is strongly recommended to provide prognostic information and therapeutic.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**REFERENCES**

1. Stewart WB, Wild CP. Breast Cancer. World Cancer Report 2014. Vol. 5. Lyon: World Health Organization; 2014. p. 362.

2. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Vol. 2. Philadelphia, USA: Elsevier Saunders; 2014. p. 1051-68.

3. Cancer Control: Knowledge Into Action: WHO Guide for Effective Programmes: Module 4: Diagnosis and Treatment. Geneva: World Health Organization; 2008.

4. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004;6:109-18.

5. Sengal AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, Kantelhardt EJ, Mohamedani AA, et al. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; Hospitals based case series. BMC Cancer 2017;17:804.

6. Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking J, et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol 2010;2:125-48.

7. Speirs V, Kerin MJ. Prognostic significance of oestrogen receptor beta in breast cancer. Br J Surg 2000;87:405-9.

8. Dotzlaw H, Levyge E, Watson PH, Murphy LC. Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res 1999;59:529-32.

9. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003;201:213-20.

10. Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: Two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 1999;54:291-313.

11. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001;8:47-61.

12. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31.

13. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.

14. Immunohistochemistry Standard Operating Protocol; 2011. Available from: http://edrn.nci.gov/resources/standard-operating-procedures/assays/IHC/immunoperoxidase-staining/sop-ihc. [Last accessed on 2017 Dec 24].

15. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.

16. ASCO-CAP HER2/neu Test Guideline Recommendations. College of American Pathologists; 2013.

17. Stewart WB, Wild CP. Cancer Worldwide. The Global and Regional Burden of Cancer. World Cancer Report 2014. Vol. 1. World Health Organization; 2014. p. 16.

18. Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, et al. Role of the multidisciplinary team in breast cancer management: Results from a large international survey involving 39 countries. Ann Oncol 2012;23:853-9.

19. Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007;31:1031-40.

20. Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: Asytematic analysis. Lancet 2011;378:1461-84.

21. Kaul R, Sharma J, Minhas SS, Mardi K. Hormone receptor status of breast cancer in the Himalayan region of northern India. Indian J Surg 2011;73:9-12.

22. AlZaman AS, Mughal SA, AlZaman YS, AlZaman ES. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. Saudi Med J 2016;37:37-42.

23. Dodiya H, Patel A, Patel D, Kaushal A, Vijay DG. Study of hormone receptors and epidermal growth factor expression in invasive breast cancers in a cohort of Western India. Indian J Clin Biochem 2013;28:403-9.

24. Ghosh S, Sarkar S, Simhareddy S, Kote S, Rao PB, Turlapati SP, et al. Clinico-morphological profile and receptor status in breast cancer patients in a south Indian institution. Asian Pac J Cancer Prev 2014;15:7839-42.

25. Rami S, Asik C, Balja MP, Paic F, Benkovic V, Knezovic F, et al. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer. Anticancer Res 2013;33:2509-15.

26. Almasri NM, Hamad MA. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res 2005;7:598-604.

27. Siadati S, Sharbatdaran M, Nikbakhhsh N, Ghaemian N. Correlation of ER, PR and HER2/neu with other prognostic factors in infiltrating ductal carcinoma of breast. Iran J Pathol 2015;10:221-6.

28. Ali EM, Ahmed RH, Ali AM. Correlation of breast cancer subtypes based on ER, PR and HER2/neu with axillary lymph node status. Cancer Oncol Res 2014;2:51-7.

29. Azizun-Nisa, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian J Clin Biochem 2013;28:403-9.

30. Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC, et al. Progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res Treat 2013;140:463-73.

31. AlZaman AS, Mughal SA, AlZaman YS, AlZaman ES. Correlation between hormone receptor status and age, and its progostic implications in breast cancer patients in Bahrain. Saudi Med J 2016;37:37-42.

32. Maha A. Correlation of hormone receptors with HER2/neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia. TJP 2010;26:209-15.